Thermo Fisher Scientific Introduces Software, Instruments, and Consumables - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Thermo Fisher Scientific Introduces Software, Instruments, and Consumables
Mar 18, 2013

Thermo Fisher Scientific launched new software, instruments, consumables, and services for analytical applications at Pittcon 2013.

Thermo Scientific Chromeleon ver. 7.2 chromatography data systems software, supports Thermo Scientific mass spectrometers and allows instruments to be integrated on enterprise-wide networks.

The Thermo Scientific Nicolet iS50 spectrometer can be upgraded from a FT-IR system to multi-range device capable of ATR, Raman, and NIR analysis without manually changing components.

The Thermo Scientific Dionex UltiMate 3000 Biocompatible Rapid Separation (BioRS) system, combines ultra-high performance liquid chromatography (UHPLC) with a corrosion-resistant flow path that can withstand high salt or extreme pH conditions.

The Thermo Scientific Dionex GlycanPac AXH-1 HPLC column allows for better analysis of glycans.

The iCAP 7000 family of inductively coupled plasma-optical emission spectrometers (ICP-OES) feature a high-resolution charged injection device (CID) imager.

The Thermo Scientific PicoSpin-45 spectrometer is a miniature NMR spectrometer designed for applied analysis in laboratories of any size.

Unity Lab SmartCapture Asset Utilization Monitoring provides automated support, service and maintenance, regardless of the instrument manufacturer.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Featured Jobs

More Jobs
3/18/2013
 Click here